“Compared with placebo, stapokibart rapidly and significantly reduced nasal polyp size, improved the main symptoms of rhinosinusitis, reduced overall sinus inflammation, and enhanced quality of life ...

HealthDay News — For patients 50 years or older at high cardiovascular risk without diabetes or prior stroke, an intensive systolic blood pressure (SBP) target (<120 mm Hg) seems cost-effective at ...

Significant decrease seen in serum levels of vascular endothelial growth factor and interleukin-1 receptor antagonist at 12 months.